Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.
Entwistle & Cappucci LLP has filed a securities class action against Cerevel Therapeutics Holdings (CERE), Bain Capital Investors, and Pfizer. The lawsuit represents investors who sold Cerevel stock between October 11, 2023, and August 1, 2024, held shares as of January 8, 2024, or sold shares around October 16, 2023.
The complaint alleges that during Cerevel's October 2023 secondary stock offering at $22.81 per share, the company omitted material information about AbbVie's interest in acquiring Cerevel. Less than two months later, AbbVie announced its acquisition of Cerevel for $45 per share. The lawsuit claims Bain Capital, as controlling shareholder, acquired shares at artificially depressed prices while possessing non-public information about AbbVie's interest, resulting in a $120 million windfall.
The action, filed in Delaware District Court, seeks damages under Sections 10(b), 14(a), 20A and 20(a) of the Exchange Act. The deadline for joining as lead plaintiff is June 3, 2025.
Entwistle & Cappucci LLP ha presentato un'azione legale collettiva in materia di titoli contro Cerevel Therapeutics Holdings (CERE), Bain Capital Investors e Pfizer. La causa rappresenta gli investitori che hanno venduto azioni Cerevel tra l'11 ottobre 2023 e il 1° agosto 2024, che possedevano azioni al 8 gennaio 2024, o che hanno venduto azioni intorno al 16 ottobre 2023.
Il reclamo sostiene che durante l'offerta secondaria di azioni di Cerevel nell'ottobre 2023 a $22,81 per azione, l'azienda ha omesso informazioni materiali riguardo all'interesse di AbbVie nell'acquisire Cerevel. Meno di due mesi dopo, AbbVie ha annunciato l'acquisizione di Cerevel per $45 per azione. La causa afferma che Bain Capital, in qualità di azionista di controllo, ha acquisito azioni a prezzi artificialmente depressi mentre possedeva informazioni riservate riguardo all'interesse di AbbVie, risultando in un guadagno di $120 milioni.
L'azione, presentata presso il Tribunale Distrettuale del Delaware, richiede danni ai sensi delle Sezioni 10(b), 14(a), 20A e 20(a) del Securities Exchange Act. La scadenza per unirsi come attore principale è il 3 giugno 2025.
Entwistle & Cappucci LLP ha presentado una demanda colectiva de valores contra Cerevel Therapeutics Holdings (CERE), Bain Capital Investors y Pfizer. La demanda representa a los inversores que vendieron acciones de Cerevel entre el 11 de octubre de 2023 y el 1 de agosto de 2024, que poseían acciones al 8 de enero de 2024, o que vendieron acciones alrededor del 16 de octubre de 2023.
La queja alega que durante la oferta secundaria de acciones de Cerevel en octubre de 2023 a $22.81 por acción, la empresa omitió información material sobre el interés de AbbVie en adquirir Cerevel. Menos de dos meses después, AbbVie anunció su adquisición de Cerevel por $45 por acción. La demanda sostiene que Bain Capital, como accionista controlador, adquirió acciones a precios artificialmente deprimidos mientras poseía información no pública sobre el interés de AbbVie, resultando en una ganancia de $120 millones.
La acción, presentada en el Tribunal de Distrito de Delaware, busca daños bajo las Secciones 10(b), 14(a), 20A y 20(a) de la Ley de Intercambio. La fecha límite para unirse como demandante principal es el 3 de junio de 2025.
Entwistle & Cappucci LLP는 Cerevel Therapeutics Holdings (CERE), Bain Capital Investors, 그리고 Pfizer를 상대로 증권 집단 소송을 제기했습니다. 이 소송은 2023년 10월 11일부터 2024년 8월 1일 사이에 Cerevel 주식을 판매한 투자자들, 2024년 1월 8일 기준으로 주식을 보유한 투자자들, 또는 2023년 10월 16일 경에 주식을 판매한 투자자들을 대표합니다.
소장에 따르면, Cerevel의 2023년 10월 주식 2차 공모가 주당 $22.81일 당시, 회사는 AbbVie의 Cerevel 인수 관심에 대한 중요한 정보를 누락했다고 주장합니다. 두 달도 채 지나지 않아 AbbVie는 Cerevel을 주당 $45에 인수한다고 발표했습니다. 이 소송은 Bain Capital이 지배주주로서 AbbVie의 관심에 대한 비공식 정보를 보유한 채 인위적으로 낮은 가격에 주식을 매입하여 1억 2천만 달러의 이익을 얻었다고 주장합니다.
이 사건은 델라웨어 지방법원에 제출되었으며, 증권 거래법의 10(b), 14(a), 20A 및 20(a) 조항에 따라 손해 배상을 요구하고 있습니다. 주도 원고로 참여하기 위한 마감일은 2025년 6월 3일입니다.
Entwistle & Cappucci LLP a déposé une action collective en valeurs mobilières contre Cerevel Therapeutics Holdings (CERE), Bain Capital Investors et Pfizer. La plainte représente les investisseurs qui ont vendu des actions de Cerevel entre le 11 octobre 2023 et le 1er août 2024, qui détenaient des actions au 8 janvier 2024, ou qui ont vendu des actions autour du 16 octobre 2023.
La plainte allègue que lors de l'offre secondaire d'actions de Cerevel en octobre 2023 à 22,81 $ par action, la société a omis des informations matérielles concernant l'intérêt d'AbbVie à acquérir Cerevel. Moins de deux mois plus tard, AbbVie a annoncé son acquisition de Cerevel pour 45 $ par action. La plainte affirme que Bain Capital, en tant qu'actionnaire majoritaire, a acquis des actions à des prix artificiellement déprimés tout en détenant des informations non publiques sur l'intérêt d'AbbVie, ce qui a entraîné un gain de 120 millions de dollars.
L'action, déposée auprès du tribunal de district du Delaware, demande des dommages-intérêts en vertu des sections 10(b), 14(a), 20A et 20(a) de la loi sur les valeurs mobilières. La date limite pour rejoindre en tant que plaignant principal est le 3 juin 2025.
Entwistle & Cappucci LLP hat eine Sammelklage gegen Cerevel Therapeutics Holdings (CERE), Bain Capital Investors und Pfizer eingereicht. Die Klage vertritt Investoren, die Cerevel-Aktien zwischen dem 11. Oktober 2023 und dem 1. August 2024 verkauft haben, die am 8. Januar 2024 Aktien hielten oder die rund um den 16. Oktober 2023 Aktien verkauft haben.
Die Beschwerde behauptet, dass das Unternehmen während des sekundären Aktienangebots von Cerevel im Oktober 2023 zu einem Preis von 22,81 $ pro Aktie wesentliche Informationen über das Interesse von AbbVie an der Übernahme von Cerevel weggelassen hat. Weniger als zwei Monate später gab AbbVie die Übernahme von Cerevel für 45 $ pro Aktie bekannt. Die Klage behauptet, dass Bain Capital als Mehrheitsaktionär Aktien zu künstlich gedrückten Preisen erworben hat, während es über nicht öffentliche Informationen bezüglich des Interesses von AbbVie verfügte, was zu einem Gewinn von 120 Millionen $ führte.
Die Klage, die beim Bezirksgericht Delaware eingereicht wurde, fordert Schadensersatz gemäß den Abschnitten 10(b), 14(a), 20A und 20(a) des Wertpapiergesetzes. Die Frist für den Beitritt als Hauptkläger ist der 3. Juni 2025.
- None.
- Class action lawsuit filed against company for alleged securities violations
- Allegations of material information omission during secondary stock offering
- Claims of insider trading against controlling shareholder Bain Capital
- Potential legal liabilities and damages under multiple sections of Exchange Act
Insights
This securities class action against Cerevel Therapeutics, Bain Capital, and Pfizer represents a significant legal challenge with potentially serious financial and regulatory implications. The lawsuit alleges multiple securities law violations connected to Cerevel's October 2023 secondary offering and subsequent
The core allegations are particularly concerning: that Cerevel and other defendants deliberately withheld material information about AbbVie's acquisition interest during the October offering, artificially depressing the
This case involves multiple serious claims under Sections 10(b), 14(a), 20A and 20(a) of the Exchange Act. The class period spans October 2023 through August 2024, with significant financial exposure for all defendants. Securities fraud litigation typically involves lengthy proceedings, substantial legal costs, and potential settlements.
The June 3, 2025 lead plaintiff deadline means this case is in its early stages, but investors should monitor developments closely as securities class actions often impact corporate governance, management focus, and can create material financial liabilities.
This securities class action poses material financial risk to Cerevel beyond just legal defense costs. The allegations strike at the heart of the
Most concerning is the
The inclusion of Pfizer as a defendant adds complexity, suggesting the plaintiffs believe the pharmaceutical giant may share liability for the alleged securities violations. For current AbbVie shareholders (following the completed merger), this litigation creates uncertainty around potential financial obligations Cerevel may have carried into the combined entity.
While impossible to predict outcomes at this early stage, similar securities cases involving timing discrepancies between offerings and acquisition announcements have resulted in material settlements. The lead plaintiff deadline of June 3, 2025, indicates this litigation will remain active for an extended period, creating ongoing uncertainty for the company.
(a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants’ violations of Section 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”); (b) held shares of Cerevel as of January 8, 2024 (the “Record Date”) and were entitled to vote on the merger of Cerevel and AbbVie Inc. (“AbbVie”) and thus were damaged by defendants’ violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain’s purchase of shares on or about October 16, 2023 and thus were damaged by Bain’s violations of Section 20A of the Exchange Act.
The Action seeks to recover damages resulting from defendants’ omissions and other wrongdoing in connection with Cerevel’s October 16, 2023 secondary stock offering (the “October Offering” or “Offering”). In this regard, the complaint alleges that Cerevel’s Offering documents and other public statements omitted material facts regarding AbbVie’s interest in acquiring Cerevel at a price well in excess of the
The Action also seeks to recover damages on behalf of investors that held shares as of the January 8, 2024 Record Date and were damaged as a result of defendants’ allegedly false and misleading statements and omissions of material facts in Cerevel’s January 18, 2024 Proxy statement (the “Proxy”). Among other things, the complaint alleges the Proxy misled investors regarding the true nature and timing of AbbVie’s interest in Cerevel.
The Action was filed in the United States District Court for the District of
If you wish to serve as a lead plaintiff in this matter, you must file a motion with the Court no later than June 3, 2025. Any member of the proposed Class may move the Court to serve as a lead plaintiff through counsel of their choice, or they may choose to do nothing and remain a member of the Class.
If you wish to discuss this Action or have any questions concerning this notice or your rights or interests, please contact: Robert N. Cappucci, Esq. or Andrew M. Sher, Esq. of Entwistle & Cappucci at (212) 894-7200 or via e-mail at rcappucci@entwistle-law.com or asher@entwistle-law.com.
About Entwistle & Cappucci
Entwistle & Cappucci is a national law firm providing exceptional legal representation to clients in the most complex and challenging legal matters. Our practice encompasses all areas of litigation, corporate transactions, bankruptcy, insurance, corporate investigations and white-collar defense. Our clients include public and private corporations, major hedge funds, public pension funds, governmental entities, leading institutional investors, domestic and foreign financial services companies, emerging business enterprises and individual entrepreneurs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250404542183/en/
Entwistle & Cappucci LLP
www.entwistle-law.com
Robert N. Cappucci, Esq. (rcappucci@entwistle-law.com)
Andrew M. Sher, Esq. (asher@entwistle-law.com)
230 Park Avenue, 3rd Floor
Telephone: (212) 894-7200
Source: Entwistle & Cappucci LLP
FAQ
What are the allegations in the class action lawsuit against Cerevel (CERE)?
How much did Bain Capital allegedly profit from the CERE stock offering?
What is the deadline to join the CERE class action as lead plaintiff?
What is the class period for the Cerevel (CERE) securities lawsuit?
